TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06683014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).
Study: NCT06688214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping treatment
Description: Therapeutic KT application administered to patients in group A. The KT treatment was completed in compliance with Kase's recommended methodology for rotator cuff tendinitis/impingement. Initially, an inhibitory approach was used to apply a supraspinatus Y-strip from its insertion to its origin. The measurement of the strip's length was taken from the acromion to the scapular spine. The base of the strip was later applied to the tuberculum major while the patient was seated; the superior tale of the Y-strip was then terminated at the superomedial angle of the scapula, passing between the middle and superior fibers of the trapezius with light tension (% 15-25); the shoulder was then extended, adducted, and internally rotated with cervical contralateral bending; the final portion of the tape (2.5-5 cm) was applied painlessly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular Stabilization Exercises
Description: Participants in Group B engage in a twice-weekly, supervised SSE exercise program that is based on the clinical decision algorithm that has been recommended by an expert panel. The goal of scapular orientation training was to normalize the scapula's resting posture and enhance proprioception. Subsequently, three scapular control exercises were executed: a closed kinetic chain exercise known as the unilateral bench press, bilateral shoulder flexion up to 60°, and a scapular control exercise including bilateral shoulder retraction and extension in the prone position. There was no discomfort involved in performing the exercises, and each session may consist of no more than four exercises. The dosage and progressions were based on the objectives of each exercise; each exercise was performed 8-10 times with a 5- to 10-second hold in between, and there was a 30-to 1-minute rest period.
Study: NCT06688279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercise
Description: . The session will last for 60 minutes and 3 times per week. 5 minutes warm up with dynamic stretching and 5 minutes cool down period with static stretching and 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set (total 3 sets).~Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step. Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard exercises protocol
Description: The session will last for 60 minutes and 3 times per week. Following exercises would be performed.~* Push ups.~* Sit ups.~* Lunges~* 500 m running.~* Squats Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test.
Study: NCT06688162

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)
Description: This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
Study: NCT06623422

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study: NCT05661695

Intervention type: DEVICE
Group type: OTHER
Intervention: RT Assistant
Description: RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
Study: NCT06623422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: IM injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IM injection
Study: NCT06626035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone based ERAS
Description: Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision \[pre-CPB in CS\] and 0.05 mg at the end of surgery \[after CPB in CS\]) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC non-methadone based group
Description: Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
Study: NCT05751226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: semaglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: semaglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05717712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-TD-nsIL12
Description: After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3 days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
Study: NCT05751226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 456906
Description: BI 456906
Study: NCT05864846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution [Epidiolex]
Description: 100 mg/ml Cannabidiol Oral solution
Study: NCT05063552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT04793984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carragelose
Description: inhalation 3 times a day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: inhalation 3 times a day
Study: NCT06627647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered as one intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT06693674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto Pill
Description: Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients taking placebo tablets will take 1 tablet orally, twice daily
Study: NCT06502977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: IV infusion
Study: NCT05215054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gana V®
Description: Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra®
Description: Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
Study: NCT06625931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTCB01-1
Description: 3 Days infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTCB-P
Description: 3 Days infusion
Study: NCT05419388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669
Description: Participants will receive intravenous (IV) RO7247669 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669
Description: Participants will receive intravenous (IV) RO7247669 Q3W
Study: NCT06188208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVD-130850
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVD-130850
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVD-130850
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVD-130850
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT06634004

Intervention type: OTHER
Intervention: BOLD MRI
Description: The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.

Intervention type: OTHER
Intervention: BOLD MRI
Description: The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.
Study: NCT06632327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Give cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Give cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Give Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Give Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Give Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Give Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Give Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Give Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Give Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Give Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Give Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Give Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Give Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Give Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Give Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Give Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Give Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Give Atezolizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06632444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT06054802

Intervention type: DEVICE
Intervention: eCAP
Description: eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
Study: NCT06406452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable Tracheobronchial Splint
Description: Subjects will have several imaging and bronchoscopic studies and the placement of the splint will require an open-chest surgery to implant the airway splint (s).~The Materialise Bioresorbable Tracheobronchial Splint is designed for an individual subject based on Computed Tomography (CT) scans taken using a specific scan protocol. Based on these 3D models, a pre-operative plan is discussed between the Materialise engineering team and the treating surgeon(s) to determine the locations and required dimensions of the splint(s). Each subject may receive up to four splints positioned on subject's trachea or mainstem bronchi.~Subjects will also have several follow-up visits, and parents will be expected to regularly fill out questionnaires.
Study: NCT06130566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Injection solution SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Injection solution SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection solution SC injection
Study: NCT04918316

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corneal gas permeable lens
Description: Fit in corneal gas permeable contact lens first.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corneal gas permeable lens
Description: Fit in corneal gas permeable contact lens first.
Study: NCT05931380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06692244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration Surgery Using Additive-Manufactured Personalized Titanium Mesh
Description: Preoperative CBCT datas of participants are obtained to design and manufacture personalized titanium meshes.Use additive-manufactured personalized titanium meshes for guided bone regeneration.In the bone grafting surgery, the additive-manufactured personalized titanium mesh is used to secure the bone substitutes, with fixation screws used to secure the titanium mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Bone Regeneration Surgery Using Prefabricated Titanium Mesh
Description: In bone grafting surgery, prefabricated titanium mesh is used to fix the bone substitutes, and fixation screws are used to secure the titanium mesh.
Study: NCT06684418

Intervention type: DIAGNOSTIC_TEST
Intervention: chest enhanced CT
Description: This is an observational study and patients will receive routine clinical treatment according to the corresponding guidelines. We will collect the enrolled patient's chest enhanced CT and clinicopathological parameters.

Intervention type: DIAGNOSTIC_TEST
Intervention: chest enhanced CT
Description: This is an observational study and patients will receive routine clinical treatment according to the corresponding guidelines. We will collect the enrolled patient's chest enhanced CT and clinicopathological parameters.
Study: NCT06701955

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and Physical Exam
Description: self administered questionnaires
Study: NCT06699875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trak exercise prescription protocol at home
Description: Online exercise protocol using the TRAK software. The patient will undergo 4 weeks of an exercise prescription protocol based on shoulder mobility exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation plan at home
Description: Treatment is based on therapeutic exercise following a conventional rehabilitation plan on paper. The patient will undergo 4 weeks of an exercise prescription protocol based on mobility exercises.
Study: NCT06685887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitors
Description: Tislelizumab, 200 mg, q3w
Study: NCT06705569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test)
Description: Tafamidis 61 mg free acid tablet (Test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test)
Description: Tafamidis 61 mg free acid tablet (Test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)